Novartis's corporate venturing unit leads the round for the diagnostic imaging company which was set up by UCLA faculty in 2007.
Swiss-based healthcare company Novartis’ corporate venturing unit led a $12.5m round on Monday for ImaginAb, a diagnostic imaging company.
Novartis Venture Funds was joined in the oversubscribed series A round by Merieux Developpement the healthcare investment company of Institut Merieux, a French industrial holding company, and venture investors Nextech Invest and Cycad Group as well as existing seed investor Momentum Biosciences, which is formed by faculty at US university UCLA.
Imaginab’s technology re-engineers antibodies into smaller proteins suitable for diagnostic…
